The Food and Drug Administration has approved a nasally administered influenza immunization treatment that can be taken at home. FluMist — a nasal spray vaccine that AstraZeneca initially developed as an in-office treatment two decades ago — will still require a prescription to obtain and is expected to be made available via a new online pharmacy next year, according to The New York Times.
The treatment will require people to fill out a questionnaire on the upcoming FlueMist Home website. Once approved by a pharmacist, the nasal spray will be shipped directly to the customer’s door. The current out-of-pocket cost is around $35 to $45 per dose, according to the NYT, but that may drop depending on insurance coverage.